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MortalityAbstract Background: Interest to evaluate the prognostic value of the inﬂammatory marker, IL-6
in young patients with ACS.
Methods: 140 young patients (18–40 years old) with ACS, were included in this non-randomized
prospective study. They were subjected to (a) full clinical evaluation (b) Laboratory evaluation
(c) Standard 12 leads ECG and Echocardiography and (d) coronary angiography. The patients were
divided into two groups, those with acute chest pain and positive coronary angiography (110
patients), and those with acute chest pain but with normal coronary angiography (control group,
30 patients).
Results: The IL-6 level was signiﬁcantly higher in patients with documented CAD compared to the
control group (39.56 ± 2.5 Vs 3.83 ± 0.79 P< 0.001). IL-6 level was signiﬁcantly higher in
patients with signiﬁcant lesions who needed to perform PCI (92 patients) than patients with non-
signiﬁcant atherosclerotic plaques needing just medical treatment (18 patients) (45.5 ± 23.17 Vs
9.22 ± 1.93 P< 0.001). Higher level of IL-6 in STEMI patients (63 Patients 57%) than NSTEMI
(23 Patients 21%) and UA (24 Patients 22%) (49.56 ± 23 Vs 43.5 ± 17 Vs 9.5 ± 2.53 respectively
with P< 0.001) was observed. The optimal cutoff value for IL-6 level to predict morbidity was
41 pg/ml with a sensitivity of 100%, speciﬁcity of 66%, and positive predictive value of 25%, neg-
ative predictive value of 100% and the diagnostic accuracy of 69%.
Conclusion: The use of IL-6 as a prognostic marker for ACS may be of Value; it may predict the
severity of CAD as well as the mortality and morbidity of young patients with acute coronary syn-
drome.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Coronary artery disease (CAD) is a devastating disease
precisely because an otherwise healthy person may die or be-
come disabled without warning. When the afﬂicted individual
is under the age of 40, the tragic consequences for family,
friends, and occupation are particularly catastrophic and
unexpected.
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inﬂammatory process. However, both will result in narrowing
of the coronary vascular lumen, and thus decreasing the nutri-
tional blood ﬂow.1
Active inﬂammation is detected when there are increased
numbers of inﬂammatory cells in atherosclerotic lesions2 and
elevated concentrations of inﬂammatory markers in the circu-
lation e.g. CRP and IL-6.3 Most of inﬂammatory cells, macro-
phages, T-lymphocytes and mast cells produce and secrete
inﬂammatory markers detectable in the circulation. Inﬂamma-
tory markers are important mediators in the diversiﬁed and
multi-step cascade of atherosclerosis, which ultimately leads
to the rupture of the atherosclerotic plaque.
IL-6 is a pleiotropic cytokine with a broad range of humor-
al and cellular immune effects relating to inﬂammation, host
defense, and tissue injury. It is a central mediator of the
acute-phase response and a primary determinant of hepatic
production of C-reactive protein.4,5
Although elevated levels of IL-6 have been reported in
some chronic inﬂammatory conditions, epidemiological data
evaluating the potential role of IL-6 in early atherogenesis
are sparse. Experimental studies indicate that vascular endo-
thelium and smooth muscle cells from normal and aneurysmal
arteries produce IL-6.6 Moreover IL-6 gene transcripts are ex-
pressed in human atherosclerotic lesions and it may have pro-
coagulant effects.7
Furthermore, prospective studies of apparently healthy8 as
well as high-risk3 individuals indicate that elevated level of C-
reactive protein, a potential surrogate for IL-6 activity is asso-
ciated with ﬁrst coronary and cerebro-vascular events. More-
over elevated levels of IL-6 and other acute-phase proteins
have been reported among patients with acute coronary syn-
dromes even among those without overt plaque rupture or
acute tissue trauma.9,10
2. Aim of the work
To study the use of IL6 as a diagnostic biomarker for young
patients presenting with acute coronary syndrome, and to as-
sess its prognostic value in predicting CAD severity, clinical
course and mortality.
3. Patients and methods
We reciureted 110 patients from all patients who were admit-
ted to the Critical Care Department – Kasr Al Aini – Cairo
University matching the inclusion criteria after the local Ethics
Committee approved the study protocol.
3.1. Inclusion criteria
Patients age should be P18 and less than 40 years old with
clinical and ECG criteria of acute coronary syndrome ESC
Guidelines, 11:
i. ST-segment elevation MI; deﬁned as: (a) more than
20 min lasting chest pain, (b) P0.1 mV ST elevation in
at least two contiguous leads or new left bundle branch
block on initial (ECG), and (c) Elevated cardiac markers
(either total creatine kinase (CK) or CK-MB at least
twice the upper limit of the normal range, or troponinI or T above individual hospital cut-off for myocardial
infarction).
ii. Non ST-segment elevation MI; deﬁned as: (a) more than
20 min lasting chest pain, (b) ST depression and/or T
wave abnormalities or even normal ECG, and (c) Ele-
vated cardiac markers.
iii. Unstable Angina; deﬁned as chest pain or ECG changes
compatible with ACS with normal cardiac markers.
3.2. Exclusion criteria
Patients under the age of 18 were excluded from the study, as
well as older than 40 years. Chronic illness e.g. chronic liver
disease, chronic renal failure, acute or chronic inﬂammatory
diseases e.g. rheumatoid arthritis, systemic lupus erythromato-
sis, active infection e.g. Pneumonia, UTI, malignancy and
acute coronary insufﬁciency secondary to any shock state or
secondary to traumatic injury to the heart were also excluded
from the study. Post CABG patients with acute coronary syn-
drome, and when coronary angiography is contraindicated
were excluded from the study. Patients who suffered from pre-
vious documented Acute Coronary Syndrome were also ex-
cluded from the study.
Patients who did not meet any of the exclusion criteria were
prospectively included into the study and they were followed
up for three months or demise.
All patients were informed about the nature of the study
and had to sign an informed consent to participate in the study
(including clinical and angiographic evaluation).
3.3. All patients were subjected to the following
3.3.1. Full clinical evaluation
Including history and physical examination with special
emphasis on risk factors (diabetes mellitus, hypertension, fam-
ily history, and smoking). Special attention was given for body
mass index (BMI). Patients were classiﬁed according to Killip
Classiﬁcations into12: – Class I; includes individuals with no
clinical signs of heart failure, Class II; includes individuals with
rales or crackles in the lungs, S3 or elevated venous pressure,
Class III; describes individuals with frank pulmonary edema,
Class IV describes individuals in cardiogenic shock or hypo-
tension and evidence of peripheral vasoconstriction.
3.3.2. Laboratory investigations
Routine laboratory investigation for assessment of liver and
kidney functions, blood sugar, coagulopathy and cardiac bio-
markers were done for all patients.
Serum Interleukin-6 (IL-6) level on admission by: Using hu-
man IL-6 ELISA kit, which is an in vitro enzyme-linked im-
mune-sorbent assay (competitive or sandwich technique) for
the quantitative measurement of human IL-6 in serum, plas-
ma, cell culture supernatants, and urine. This assay employs
an antibody speciﬁc for human IL-6 coated on a 96-well plate.
Samples and biotinylated anti-human IL-6 are pipetted into
the wells. IL-6 present in a sample is captured by the antibody
immobilized to the wells and by the biotinylated IL-6 speciﬁc
detection antibody. After washing away unbound biotinylated
antibody, HRP-conjugated streptavidin is pipetted into the
wells. The wells are again washed. Following this second wash
Table 1 Demographic and clinical data.
Characteristics Value
Age {mean ± SD (Range in years} 34.46 (25–39)
Male: Female sex (Ratio) 86: 24 (3.58)
Clinical diagnosis no. of patients (%)
UA 24 (22%)
NSTEMI 23 (21%)
STEMI 63 (57%)
Risk factors no of patients (%)
Diabetes Mellitus 47 (42.7%)
Hypertension 58 (52.7%)
Smoker 93 (84.5%)
+ve family history 70 (63.6%)
Dyslipedemia 20 (18.2%)
BMI {mean ± SD (Range; median)} 27.04
ECG changes no of patients (%) 106 (96.4%)
Killip classiﬁcation no of patients (%)
Killip I 100 (90.9%)
Killip II 8 (7.3%)
Killip III 2 (1.8%)
Killip IV 0 (0%)
Cardiac markers
Positive troponin no of patients (%) 86 (78.2%)
CK {mean ± SD (Range; median)}
1st day 268.36
2nd day 2018 .21
3rd day 1624.65
CK-MB {mean ± SD (Range; median)}
1st day 26.09
2nd day 175.65
3rd day 129.2
Lipid proﬁle {mean ± SD (Range; median)}
Total Cholesterol (mg/dl) 258.42
LDL (mg/dl) 158.2
HDL (mg/dl) 43.16
Triglycerides (mg/dl) 128.95
ECHO ﬁnding
EF (%) {mean ± SD (Range; median)} 55.29
RWMA N of patients (%) 67 (60.9%)
Angiographic ﬁnding
Vessel aﬀected (mean ± SD) (Range-median) 1.35
No. of vessel aﬀected no of patients (%)
Single vessel 79 (71.8%)
Two vessel 23 (20.9%)
Multi vessel 8 (7.3%)
TIMI ﬂow {mean ± SD (Range; median)} 1.1 ± 1.1 (0–3; 1)
Outcome no of patients (%)
Morbidity 11 (10%)
Mortality 3 (2.7%)
UA: unstable angina NSTEMI: non ST-segment elevation myo-
cardial infarction STEMI: ST-segment elevation myocardial
infarction EF: ejection fraction SWMA: segmental wall motion
abnormality BMI: body mass index ECG: electrocardiogram CK:
createnin kinase CK-MB: createnin kinase–MB HDL: high density
lipoprotein LDL: low density lipoprotein No: number SD: standard
deviation.
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color development proportional to the amount of IL-6 bound.
The stop solution changes color from blue to yellow and the
intensity of the color is measured at 450 nm.
Sampling was done after one hour after admission for all
patients.
3.3.3. Standard 12-lead ECG
On admission, after the coronary angiography and every 6 h
for 24 h, then daily and whenever indicated.
3.3.4. Imaging studies
(i) Echocardiography: for assessment of the ejection fraction
(EF) and the presence of RWMA.13, images were accepted
for analysis according to the guidelines proposed by Gordon
et al.14 when at least 80% of endocardium was seen. (ii) Car-
diac catheterization and percutaneous coronary intervention
with special attention to collect the following data: (a) TIMI
ﬂow grade before any procedure and after ﬁnal adjunctive
interventions and include; (Grade III (Complete Reperfusion);
Patent epicardial artery with normal ﬂow; Grade II (Partial
Reperfusion); Patent epicardial artery with opaciﬁcation of
the entire distal artery (however, contrast ﬁlling or washout
is delayed); Grade I (Penetration with Minimal Perfusion); Par-
tial contrast penetration beyond an occlusion with incomplete
distal ﬁlling., Grade 0 (No Perfusion) Absent ante grade ﬂow.15
(b) Number of vessels affected and (c) Severity of the lesions
requiring emergency bypass surgery or emergency stenting.16
N.B. Coronary angiographic signiﬁcance means coronary
lesion > 70%, or LM> 50% and requires intervention.17,18
All patients were followed up for a total period of three
months for the following: recurrence of chest pain, arrhyth-
mias either primary or secondary that require pharmacological
or interventional treatment, readmission by recurrent myocar-
dial ischemia either unstable angina or myocardial infarction,
revascularization either by PCI or CABG, heart failure deﬁned
by symptoms and sings of pulmonary congestion requiring the
use of speciﬁc therapy as diuretics, vasodilators, and inotropic
supports, or death. No drop out for our patients had occurred,
and telephone call was done for those who could not come to
the hospital.
An additional 30 patients presented with chest pain but
having normal coronary angiography were included as a con-
trol group.
3.4. The statistics
Data were statistically described in terms of range, ±standard
deviation (±SD), median, frequencies (number of cases) and
relative frequencies (percentages) when appropriate. Compari-
son of quantitative variables between the study groups was
done using Mann Whitney U test for independent samples.
For comparing categorical data, Chi square (v2) test was per-
formed. Exact test was used instead when the expected fre-
quency is <5. Accuracy was represented using the terms
sensitivity and speciﬁcity of the serum IL-6 levels. Receiver
operator characteristic (ROC) analysis was used to determine
the optimum cut off value for the studied diagnostic markers.
Correlation between various variables was done using Spear-
man rank correlation equation for non-normal variables. A
probability value (p value) less than 0.05 was considered statis-tically signiﬁcant. All statistical calculations were done using
computer programs Microsoft Excel 2003 (Microsoft Corpora-
tion, NY, USA) and SPSS (Statistical Package for the Social
Science; SPSS Inc., Chicago, IL, USA) version 18 for Micro-
soft Windows.
Table 3 IL-6 Level and Killip classiﬁcation.
Killip classiﬁcation No. Mean ± SD Median P value
Killip I 100 37.45 ± 42.21 37 0.001
Killip II 8 50.38 ± 14.02 51.5
Killip III 2 102 ± 11.31 102
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4.1. Demographic and baseline clinical data
See Table 1.
4.2. Interleukin 6 value and its correlation to other variables
The level of IL-6 level showed a marked difference between
randomized patients and the control group (mean ± SD
‘‘Range’’ 3.83 Vs 39.56 with P< 0.001). Analysis of the data
obtained from the coronary angiography showed IL-6 level
was proportional with severity of the lesions in the coronary
anatomy. It was signiﬁcantly higher in patients with signiﬁcant
lesions in the angiography (92 patients) than that of those with
non-signiﬁcant lesion (18 patients) and that of the control
group (30 patients), (mean ± SD ‘‘Range’’ 45.5 Vs 9.22 Vs
3.83 respectively with P< 0.001).
There was statistically insigniﬁcant negative correlation be-
tween IL-6 level and age (r= 168, P= 0.08). Also, there
was no statistically signiﬁcant difference in IL-6 level as re-
gards gender (mean ± SD ‘‘Range; median’’ 39.87 for male
Vs 38.46for female with P= 0.809).
Correlation of IL 6 with different risk factors for CAD
showed no signiﬁcant difference in IL-6 level as regards smok-
ing status or family history. However, the IL-6 level was statis-
tically higher in diabetic patients compared to non-diabetics,
and lower in those with history of hypertension than those
without Table 2.
Moreover, there was statistically signiﬁcant positive corre-
lation between IL-6 level (39.56 pg/ml) and BMI mean
(27.04) with (r= 0.507, P value < 0.001).
Correlation of IL 6 with different clinical parameter docu-
mented its rise with increased severity of the clinical condition.
The mean IL-6 level was statistically signiﬁcantly higher in
those with Killip class III compared to those with Killip class
II or I (Table 3).
The mean level of IL-6 was higher in those with +ve tropo-
nin test compared to those with ve troponin result
(mean ± SD 47.95 Vs with P< 0.001).
Also, there was statistically signiﬁcant positive correlation
between IL-6 level and CK level in 2nd and 3rd day in the
studied patients (r= 0.560, P value < 0.001and r= 0.508
respectively, P< 0.001) while there was no signiﬁcant correla-Table 2 IL-6 Level in relation to risk factors.
No.
Diabetes mellitus Yes 47
No 63
Smoker Yes 93
No 52
Hypertension Yes 58
No 52
Family History Yes 70
No 40
Dyslipidemia Yes 20
No 90tion between IL-6 level and CK level in 1st day (r= 0.158, P
value = 0.098). However, regarding CK-MB there was statis-
tically signiﬁcant positive correlation from day 1 and for the
two successive days. (r= 0.231, P= 0.015; r= 0.574,
P< 0.001; and r= 0.488, P< 0.001 respectively).
The IL-6 level was statistically signiﬁcantly higher in STE-
MI patients (63 patients ‘‘57%’’) compared to NSTEMI (23
patients ‘‘21%’’) and UA patients (24 patients ‘‘22%’’),
(mean ± SD ‘‘Range; median’’ 49.56 Vs 43.5 Vs 9.5 respec-
tively with P< 0.001).
There was statistically signiﬁcant positive correlation be-
tween IL-6 level and number of affected vessels (r= 0.341, P
value < 0.001) (Table 4).
The above Table 4 shows how the level of IL6 was directly
related to the number of the affected vessels.
 TIMI ﬂow: There was highly statistically signiﬁcant nega-
tive correlation between IL-6 level and TIMI Flow (Pre
PCI) (r= 0.348, P< 0.001).
4.3. IL-6 value in relation to the ﬁnal outcome
 Mortality: During the follow up period, 3 patients died due
to cardiogenic shock; the IL-6 level was statistically signiﬁ-
cantly higher in non-survivals compared to the survived
group (mean 92.33Vs 38.08 with P< 0.001).
 Morbidity: During the follow up period, out of 107 patients
survived, 6 patients had recurrent chest pain without
dynamic ECG changes or needing hospital re-admission,
2 patients were readmitted by recurrent UA/ STEMI, 2
patients subjected to surgical revascularization, and one
patient suffered from arrhythmia (Atrial Fibrillation). The
IL-6 level was statistically signiﬁcantly higher in morbid
patients compared to others (mean ± 71.4569’’ Vs 34.26
with P< 0.001).Mean ± SD Median P value
45.62 ± 26.3 46 0.028
35.05 ± 23.38 33
40.23 ± 23.29 38 0.52
45.12 ± 27.46 41.5
34.59 ± 21.86 35.5 0.027
45.12 ± 27.46 41.5
43.04 ± 25.45 39.5 0.054
33.48 ± 23.59 33.5
18.40 ± 20.37 10 <0.001
44.26 ± 23.67 41.5
Table 4 IL-6 level and number of vessels affected.
No. of vessels aﬀected No. Mean ± SD Range Median P value
Single Vessel 79 35.19 ± 23.65 6–135 35 0.001
Two Vessel 23 44.7 ± 23.68 13–91 41
Multi Vessel 8 68 ± 24.48 35–110 63.5
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Receiver operator characteristics (ROC) curve was calculated
for the use of IL-6 level as a predictor of morbidity. The area
under the ROC curve was 0.884 (95% conﬁdence interval,
0.805–0.964) with P< 0.001. The optimal cutoff value for
IL-6 level to predict morbidity was 41 pg/ml. This cutoff value
has a sensitivity of 100%, speciﬁcity of 66%, positive predic-
tive value of 25%, negative predictive value of 100% and the
diagnostic accuracy of 69% Fig. 1a.
Also, ROC curve was calculated for the use of IL-6 level as
a predictor of mortality. The area under the ROC curve was
0.963 with P= 0.006. The optimal cutoff value for IL-6 level
to predict mortality was 71 pg/ml. These cutoff values have a
sensitivity of 100%, speciﬁcity of 89%, positive predictive va-
lue of 20%, negative predictive value 100% and the diagnostic
accuracy 89% Fig. 1b.5. Discussion
Cardiac biomarkers are substances that are released into the
blood when the heart is damaged or stressed. Measurement
of these biomarkers is used to help diagnose, risk stratify,
monitor and manage people with suspected ACS and cardiac
ischemia.19
Whilst cardiac ischemia/infarction is the most prevalent
cause of cardiac injury, the search for more meaningful bio-
markers now includes those for inﬂammatory processes and
myocardial wall stress where evaluation extends beyond myo-
cardial necrosis.19
In the last few years, new biomarkers able to measure the
coronary atherosclerotic burden have been investigated. One
of these markers is IL-6, however, there were no sufﬁcient
studies demonstrating the correlation between IL-6 and ACS
in speciﬁc age group.19
Gotsman I et al.20 reported that there was signiﬁcant corre-
lation between tumor necrosis factor-alpha and interleukin-6
with the severity of CAD assessed by the number of obstructed
coronary vessels and the severity of the lesions. They found
that IL-6 is positively correlated with coronary vessel disease
(>70% stenosis) and the mean number of vessels affected (P
value < 0.001). Also, Chun-lin L et al.21 concluded that Serum
Hs-CRP and IL-6 levels can be considered as the indexes to
judge the degree of CAD and may reﬂect the activity of plaque
in CAD patients (P< 0.01).
The present study was concordant with the previous two
studies as the mean level of IL-6 was signiﬁcantly higher in
the included patients when compared to the control group.
On studying the relation of IL-6 with age and sex, it had no
signiﬁcant difference regarding those variables, and this was
concordant with Dizdarevic´ et al.22 who compared the levels
of IL-6 and IL-10 between 36 patients with ACS and 30 pa-
tients with stable angina (P> 0.05 for both the age and sex).On studying the relationship between the IL-6 and other
risk factors it was observed that there was no statistically sig-
niﬁcant difference in IL-6 Level as regards smoking status or
family history. Moniek and Cornelis,23 studied the relationship
of the inﬂammatory markers CRP, IL-6, interleukin-1b (IL-
1b) and tumor necrosis factor-a (TNF-a) in smokers and
non-smokers. They found that IL-6 and TNF-a were signiﬁ-
cantly higher in patients than in controls, both in smokers
and in non-smokers.
However, we demonstrated that IL-6 level was signiﬁcantly
higher in diabetic patients compared to non-diabetic patients,
which is concordant with Paresh et al. and Yaseen et al.24,25 as
they concluded that baseline IL-6 was elevated in diabetic pa-
tients than non-diabetic patient. These observations can be ex-
plained by that leptin and ROS potentiate the release of
circulating cytokines.
Regarding hypertension, the IL-6 level was signiﬁcantly
lower in hypertensive patients when compared with those not
hypertensive. This observation was discordant with Bautista
et al.26 who found that the mean levels of IL-6 were signiﬁcantly
higher in hypertensive patients when compared with those not
hypertensive. This can be explained by that most of the non-
hypertensive patients in our study had other risk factors as dia-
betes mellitus and dyslipidemia, which elevate IL-6 level.
In the present study, there was statistically signiﬁcant posi-
tive correlation between IL-6 level and BMI mean and this was
in concordance with Kaenig27 who found that the patients
with higher BMI had elevated serum IL-6 level.
Also we demonstrated that the IL-6 level was statistically
signiﬁcantly higher in those with ECG changes suggestive of
CAD as well as those with RWMA at echocardiography when
compared with those without these changes (P= 0.02, 0.003
respectively). This matches with the result of a study done by
Kaenig27 who studied 156 patients with ACS and they found
that the median level of IL-6 in patient with ACS was
(27.2 pg/ml) while in the stable group without ECG changes
was (13.4 pg/ml) with a P value of 0.01. Moreover Ikonomidis
et al.28 reported that greater release of IL-6 at peak stress and
recovery was observed in patients with increasing number of
ischemic segments observed with Echocardiography.
There was statistically signiﬁcant negative correlation be-
tween IL-6 level and EF (%) in the included patients
(r= 0.354, P< 0.001). This result was supported by a study
done by Lopez et al.29 who collected 216 hospitalized patients
with ACS and detected baseline serum CRP and IL-6 level;
they found a signiﬁcant negative correlation between IL-6 level
and EF% (P= 0.019).
Moreover, IL-6 level was statistically signiﬁcantly higher in
those with KILLIP Class III compared to those with KILLIP
Class I or II. This result is concordant with Tsutamoto et al.30
that detected that the Interleukin-6 in the peripheral circula-
tion increases with the severity of heart failure (P< 0.01),
and the high plasma level of IL-6 is an important prognostic
predictor in patients with congestive heart failure.
Figure 1 ROC for morbidity (A) and mortality (B).
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diac biomarkers showed that IL-6 was statistically signiﬁcantly
higher in those with +ve Troponin results compared to nega-
tive patients. There was statistically signiﬁcant positive correla-
tion between IL-6 level and serum CK level in 2nd and 3rd day
only, however, CK-MB in ﬁrst, second and third day of ran-
domization. This might be attributed to CK-MB being more
sensitive, speciﬁc and appears earlier in serum than CK. A
study performed by Triyono et al.31 reported that IL-6 was
moderately related to troponin as a marker of acute myocar-
dial injury supporting this observation.
Regarding the angiographic results, there was a signiﬁcant
correlation between IL-6 level and the number of diseased ves-
sels (r= 0.341 with P< 0.001). Also we found that there was
a highly statistically signiﬁcant negative correlation between
IL6 level and TIMI ﬂow (Pre PCI) (r= 0.348 with
P< 0.001). This result is supported by the study performed
by EL Oudi et al.32 who made a comparison of biological
parameters including IL-6 with the number of diseased arteries
in acute coronary syndrome patients and found highly signiﬁ-
cant correlation between the mean levels of IL-6 and the num-
ber of diseased vessels (P< 0.001).
During 3 months of follow up, only 3 patients died by car-
diogenic shock. It was noticed that the mean level of IL-6 was
statistically signiﬁcantly higher in non-survivors when com-
pared to the survivors. The ROC analysis used in our study re-
vealed that the optimal cut off value for IL-6 level to predict
mortality was 71 pg/ml and this value gave a sensitivity of
100% and speciﬁcity of 89%. Regarding the morbidity; out
of 107 Patients survived, 6 Patients had recurrent chest pain
without dynamic ECG changes or needing hospital admission,
2 Patients were admitted by UA/ STEMI, 2 Patients subjected
to surgical revascularization, and one patient suffered from
arrhythmia (Atrial Fibrillation). It was noticed that the mean
level of IL-6 in these patients was signiﬁcantly higher com-pared to uncomplicated patients. The ROC analysis revealed
that the optimal cutoff value for IL-6 level to predict morbidity
was 41 pg/ml and this value gave a sensitivity of 100% and
speciﬁcity of 66%.
In young patients with a single culprit lesion, a plaque rup-
ture on a previously non-signiﬁcant vulnerable plaque is usu-
ally the mechanism of acute presentation. Such cases are
likely related to acute physical and/or emotional stress, result-
ing in enhanced coronary shear forces. If these patients do not
alter their lifestyles, CAD progression at an earlier age than
usual will result, but it may be avoided by following estab-
lished preventive measures. This group has a substantial vaso-
spastic component superimposed on a genetic predisposition
to vulnerable plaque production.33
Conversely, a second group is comprised of those with dia-
betes and others who present with established multi-vessel dis-
ease (including those related to lipid abnormalities). These
patients are most likely to have rapid progression of a more
typical form of CAD. They will experience only short-term
beneﬁt from revascularization, unless very aggressive control
over risk factors is strictly adhered.33
Active inﬂammation and certain morphological and func-
tional features characterize atherosclerotic plaques, which are
vulnerable to rupture. Active inﬂammation is detected as in-
creased numbers of inﬂammatory cells in atherosclerotic le-
sions and as elevated concentrations of inﬂammatory
markers in the circulation e.g. CRP. Major inﬂammatory cells,
macrophages, T lymphocytes and mast cells, produce and se-
crete inﬂammatory markers detectable in the circulation.
Inﬂammatory markers are important mediators in the diversi-
ﬁed and multi-step cascade of atherosclerosis that ultimately
leads to the rupture of the atherosclerotic plaque.34 The inter-
action between a genetic propensity to form vulnerable plaque
combined with acute stress and/or an active inﬂammatory pro-
cess needs further study.
Prognostic value of IL6 in young adults presenting with acute coronary syndrome 1576. Conclusion, limitations and recommendation
The inﬂammatory marker; IL-6 (measured by ELIZA which
is a relatively simple, rapid and easy assay) may be a poten-
tially useful marker for the evaluation of acute coronary syn-
drome in young adults. It is a simple test for evaluating the
prognosis of these patients, predicting mortality and morbid-
ity. However, due to small sample size of this study, we rec-
ommend to perform a large randomized trial to Asses the
sensitivity and speciﬁcity of IL 6 in young adults presenting
with Acute Coronary Syndrome. Other limitation of this
study that we used the number of vessels affected rather than
myocardium at risk to correlate with level of IL6, so we can
predict the prognosis of the patients. If we can better identify
and characterize the mechanism of disease in this population,
our understanding of CAD in more typical cases will be
vastly improved.Conﬂict of interest
None declared.References
1. Fuster V, Moreno P, Fayad Z, et al. Atherothrombosis and high-
risk plaque: part I: evolving concepts. J Am Coll Cardiol
2005;46:937–54.
2. Van der Wal A, Becker A, et al. Site of intimal rupture or erosion
of thrombosed coronary atherosclerotic plaques is characterized
by an inﬂammatory process irrespective of the dominant plaque
morphology. Circulation 1994;89:36–44.
3. Haverkate F, Thompson S, Pyke S, et al. Production of C-reactive
protein and risk of coronary events in stable and unstable angina.
European concerted action on thrombosis and disabilities angina
pectoris study group. Lancet 1997;349:462–6.
4. Zamani P, Schwartz G, Olsson A, et al. Inﬂammatory biomark-
ers, death, and recurrent nonfatal coronary events after an acute
coronary syndrome in the MIRACL study. J Am Heart Assoc
2013;2(1):e003103.
5. Packard R, Libby P. Inﬂammation in atherosclerosis: from
vascular biology to biomarker discover and risk prediction. Clin
Chem 2008;54:24–38.
6. Rus H, Niculescu F. Inﬂammatory response in unstable angina.
Circulation 1999;100:e98.
7. Annemieke M, Robbert J, Monique C, et al. Procoagulant and
proinﬂammatory activity in acute coronary syndromes. Cardiovasc
Res 1998;40(2):389–95.
8. Ridker P, Buring J, Shih J, et al. Prospective study of C-reactive
protein and the risk of future cardiovascular events among
apparently healthy women. Circulation 1998;98:731–3.
9. Liuzzo G, Biasucci L, Gallimore J, et al. The prognostic value of
C-reactive protein and serum amyloid A protein in severe unstable
angina. N Engl J Med 1994;33:1417–24.
10. Chun-lin LAI, You-rui JI, et al. Relationship between coronary
atherosclerosis plaque characteristics and high sensitivity C-
reactive proteins, interleukin-6. Chin Med J 2011;124(16):2452–6.
11. The Task Force for the management of acute coronary syndromes
(ACS) in patients presenting without persistent ST-segment
elevation of the European Society of Cardiology (ESC). Christian
W, Jean-Pierre B, Stefan A, et al. European Heart Journal 2011;
32, 2999–3054.
12. Killip T, Kimball J. Treatment of myocardial infarction in a
coronary care unit. A two year experience with 250 patients. Am J
Cardiol 1967;20(4):457–64.13. Sahn D, DeMaria A, Kisslo J, Weyman A. Recommendations
regarding quantitation in M-mode echocardiography: – results of
a survey of echocardiographic measurements. Circulation
1978;58:1072–83.
14. Gordon E, Ingela S, Peter J. Reproducibility of left ventricular
volumes by two-dimensional echocardiography. J Am Coll Cardiol
1983;2:506–13.
15. Gibson C, Murphy S, Rizzo M, et al. Thrombolysis In Myocar-
dial Infarction (TIMI) study group. Relationship between TIMI
frame count and clinical outcomes after thrombolytic administra-
tion. Circulation 1999;99:1945–50.
16. Laurent B, Laurence C, Ste´phane A, et al. Adjusted clopidogrel
loading doses according to vasodilator-stimulated phosphoprotein
phosphorylation index decrease rate of major adverse cardiovas-
cular events in patients with clopidogrel resistance: a multicenter
randomized prospective study. this study was granted by the
Federation Francaise de Cardiologie, Paris, France. Reprint
requests and correspondence: Dr. Laurent Bonello, De´partement
de Cardiologie, Hoˆpital Universitaire Nord, Chemin des Bourrely,
13015, Marseille, France. American College of Cardiology Foun-
dation. J Am Coll Cardiol 2008;51(14):1404–11.
17. Grube E, Bootsveld A, Buellesfeld L, et al. Computerized two-
lead resting ECG analysis for the detection of coronary artery
stenosis after coronary revascularization. Int J Med Sci
2008;5(2):50–61.
18. Hosokawa J, Shen J, Imhoff M. Computerized 2-lead resting ECG
analysis for the detection of relevant coronary artery stenosis in
comparison with angiographic ﬁndings. Cong Heart Failure
2008;14:251–60.
19. Anthony S, Stephen J. Cardiac biomarkers in the intensive care
unit. Ann Intensive Care 2012;2:8.
20. Gotsman I, Stabholz A, Planer D1, et al. Serum cytokine tumor
necrosis factor-alpha and Interleukin-6 associated with the severity
of coronary artery disease: indicators of an active inﬂammatory
burden? IMAJ 2008;10:494–8.
21. Chun-lin L, LAI Chun-lin, You-rui J, Xiao-hong L, et al.
Relationship between coronary atherosclerosis plaque character-
istics and high sensitivity C-reactive proteins, interleukin-6.
Chinese Med J 2011;124(16):2452–6.
22. Dizdarevic´-Hudic´ L, Kusˇljugic´ Z, Barakovic´ F, et al. Correlation
between Interleukin 6 and interleukin 10 in acute myocardial
infarction. Bosnian J Basic Med Sci 2009;9(4):301–6.
23. Moniek P, Cornelis K. The association between inﬂammation
markers, coronary artery disease and smoking. Vas Pharmacol
2002;39:137–9.
24. Paresh D, Ahmad A, Arindam B. Inﬂammation: the link between
insulin resistance, obesity and diabetes. Trends Immunol
2004;25:4–7.
25. Yaseen F, Anila J, Jawed A, et al. Circulating levels of resisting,
IL-6 and lipid proﬁle in elderly patients with ischemic heart disease
with and without diabetes. Future Med J February
2012;6(1):97–102.
26. Bautista L, Gamarra G, et al. Independent association between
inﬂammatory markers (C-reactive protein, interleukin-6, and
TNF-) and essential hypertension. J Human Hyperten
2005;19:149–54.
27. Kaenig W, Gregory Y, Muzahir T, et al. Circulating endothelial
cells, von Willebrand factor, interleukin-6, and prognosis in
patients with acute coronary syndromes. Blood J 2005;105:526–32.
28. Ikonomidis I, Athanassopoulos G, Lekakis J, et al. Myocardial
ischemia induces interleukin-6 and tissue factor production in
patients with coronary artery disease: a dobutamine stress
echocardiography study. Circulation, 2005 22(21);112:3272–9.
29. Lopez A, Sergio M, Gregory Y, et al. Interleukin-6 and High-
sensitivity C-reactive protein for the prediction of outcomes in non
ST segment elevation acute coronary syndromes. REVISTA
ESPAN˜OLA DE CARDIOLOGI´A (English edition)
2012;66(3):185–92.
158 A. Mowafy et al.30. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover
in the peripheral circulation increases with the severity of heart
failure, and the high plasma level of interleukin-6 is an important
prognostic predictor in patients with congestive heart failure. J Am
Coll Cardiol 1998;31:391–8.
31. Triyano T, Pariding J, Sukorini U. Correlation of IL-6 and
monocyte count to Troponin I in acute coronary syndrome.
Berkala Ilmu kedokteran 2008;40(4):189–92.32. EL Oudi M, Zied A, Chakib M, et al. Homocysteine and markers
of inﬂammation in acute coronary syndrome. Exp Clin Cardiol
2010;15(2):25–8.
33. Nevas N, Colangelo L, Beam C, et al. Risk factors for coronary
heart disease in men age 18–39 years of age. Ann Intern Med
2001;134:433–9.
34. Virmani R, Burke A, Farb A, et al. Pathology of the vulnerable
plaque. J Am Coll Cardiol 2006;47:13–8.
